Their unique niche in the enzyme family of the carbonic anhydrases has long made them interesting targets for anti-cancer therapy as their expression in healthy tissue is by far not as widespread as the expression of other members of their enzyme family, e.g., carbonic anhydrase II or IV. The gene discussed is CA2; the disease is cancer.